Literature DB >> 26276716

Reprogramming cancer cells: a novel approach for cancer therapy or a tool for disease-modeling?

Açelya Yilmazer1, Irene de Lázaro2, Hadiseh Taheri3.   

Abstract

Chromatin dynamics have been the major focus of many physiological and pathological processes over the past 20 years. Epigenetic mechanisms have been shown to be reshaped during both cellular reprogramming and tumorigenesis. For this reason, cancer cell reprogramming can provide a powerful tool to better understand both regenerative and cancer-fate processes, with a potential to develop novel therapeutic approaches. Recent studies showed that cancer cells can be reprogrammed to a pluripotent state by the overexpression of reprogramming transcription factors. Activation of transcription factors and modification of chromatin regulators may result in the remodeling of epigenetic status and refueling of tumorigenicity in these reprogrammed cancer cells. However, studies focusing on cancer cell reprogramming are contradictory; some studies reported increased tumor progression whereas others showed that cellular reprogramming has a treatment potential for cancer. In this review, first, the current knowledge on the epigenetic mechanisms involved during cancer development and cellular reprogramming will be presented. Later, different reports and key factors about pluripotency-based reprogramming of cancer cells will be reviewed in detail. New insights will be provided on cancer biology and therapy in the light of cellular reprogramming.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Cell reprogramming; Epigenetics; Transcription factors; iPS cells

Mesh:

Substances:

Year:  2015        PMID: 26276716     DOI: 10.1016/j.canlet.2015.06.027

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

1.  Human acute leukemia induced pluripotent stem cells: a unique model for investigating disease development and pathogenesis.

Authors:  Clara Bueno; Pablo Menendez
Journal:  Stem Cell Investig       Date:  2017-06-13

2.  Pluripotency Stemness and Cancer: More Questions than Answers.

Authors:  Jiří Hatina; Michaela Kripnerová; Zbyněk Houdek; Martin Pešta; Filip Tichánek
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

3.  Tendency of K562 Chronic Myeloid Leukemia Cells Towards Cell Reprogramming

Authors:  Açelya Yılmazer Aktuna
Journal:  Turk J Haematol       Date:  2018-05-21       Impact factor: 1.831

4.  Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency.

Authors:  Alvaro Muñoz-López; Damià Romero-Moya; Cristina Prieto; Verónica Ramos-Mejía; Antonio Agraz-Doblas; Ignacio Varela; Marcus Buschbeck; Anna Palau; Xonia Carvajal-Vergara; Alessandra Giorgetti; Anthony Ford; Majlinda Lako; Isabel Granada; Neus Ruiz-Xivillé; Sandra Rodríguez-Perales; Raul Torres-Ruíz; Ronald W Stam; Jose Luis Fuster; Mario F Fraga; Mahito Nakanishi; Gianni Cazzaniga; Michela Bardini; Isabel Cobo; Gustavo F Bayon; Agustin F Fernandez; Clara Bueno; Pablo Menendez
Journal:  Stem Cell Reports       Date:  2016-09-22       Impact factor: 7.765

5.  Reprogramming A375 cells to induced‑resembled neuronal cells by structured overexpression of specific transcription genes.

Authors:  Hengzhu Zhang; Min Wei; Yangyang Jiang; Xiaodong Wang; Lei She; Zhengcun Yan; Lun Dong; Lujun Pang; Xingdong Wang
Journal:  Mol Med Rep       Date:  2016-08-08       Impact factor: 2.952

6.  Using patient-derived iPSCs to develop humanized mouse models for chronic myelomonocytic leukemia and therapeutic drug identification, including liposomal clodronate.

Authors:  Kazuki Taoka; Shunya Arai; Keisuke Kataoka; Masataka Hosoi; Masashi Miyauchi; Sho Yamazaki; Akira Honda; Wei Aixinjueluo; Takashi Kobayashi; Keiki Kumano; Akihide Yoshimi; Makoto Otsu; Akira Niwa; Tatsutoshi Nakahata; Hiromitsu Nakauchi; Mineo Kurokawa
Journal:  Sci Rep       Date:  2018-10-26       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.